Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Sep 07, 2021 9:30am
133 Views
Post# 33818156

RE:RE:RE:RE:More coverage in China

RE:RE:RE:RE:More coverage in China It seems like there are more coverage of the targeted drug delivery now, all these frequent articles are new, never came across them before!

Recently, another biomedical company called Theratechnologies also announced the research progress of two PDCs in its R&D pipeline. Up to now, two PDC products have been approved worldwide, and a number of PDC products have entered the clinical stage. At present, this field has attracted international pharmaceutical giants including Novartis, AstraZeneca, Roche, etc. to deploy one after another. Domestic innovative drug companies such as Sheng Nuoji Pharmaceutical and Mainstream Biology have also begun to conduct PDC research and development.

Based on its versatility and advantages, PDC is a research field with broad development prospects. As more innovative biomedical companies join, PDC drugs are expected to achieve rapid development.

 

https://m.jrj.com.cn/madapter/stock/2021/09/07085333396635.shtml

<< Previous
Bullboard Posts
Next >>